Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.59 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.51 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.50 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 2/20 | 0.47 |
| ▸ | PYGM | P11217 | 1/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275706 | 0.92 | SERPINE1 (0.58) | ACLYSERPINE1KCNK2KCNK10PYGL | |
| SCHEMBL2272613 | 0.91 | LMNA (0.56) | ACLYRXFP1PYGL | |
| SCHEMBL2272432 | 0.90 | PYGL (0.55) | ACLYSERPINE1KCNK2KCNK10P2RX1 | |
| SCHEMBL2277696 | 0.87 | MPO (0.59) | KCNK2KCNK10RXFP1PYGLPYGM | |
| SCHEMBL14428477 | 0.86 | P2RX1 (0.46) | ACLYTLR8RXFP1P2RX1 | |
| SCHEMBL2271588 | 0.85 | SERPINE1 (0.64) | SERPINE1PYGLPYGMHPSE | |
| SCHEMBL2276447 | 0.84 | SERPINE1 (0.54) | SERPINE1CYP2C9CYP2C19PYGLPYGM | |
| SCHEMBL2274737 | 0.84 | AVPR2 (0.49) | SERPINE1KCNK2KCNK10RXFP1PYGL | |
| SCHEMBL1534369 | 0.82 | RXFP1 (0.68) | ACLYKCNK2KCNK10RXFP1P2RX1 | |
| SCHEMBL2276272 | 0.82 | MEN1 (0.58) | SERPINE1RXFP1CYP2C9CYP2C19PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885SERPINE1 101/4885KCNK2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.